NewAmsterdam Pharma Company NV
NAMS34.300USD
+2.240+6.99%
終値 02/06, 16:00（ET）15分遅れの株価
3.88B時価総額
損失額直近12ヶ月PER
詳細情報 NewAmsterdam Pharma Company NV 企業名
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
NewAmsterdam Pharma Company NVの企業情報
企業コードNAMS
会社名NewAmsterdam Pharma Company NV
上場日Nov 23, 2022
最高経営責任者「CEO」Davidson (Michael Harvey)
従業員数68
証券種類Ordinary Share
決算期末Nov 23
本社所在地Gooimeer 2-35
都市NAARDEN
証券取引所NASDAQ OMX - NASDAQ BASIC
国Netherlands
郵便番号1411 DC
電話番号31352062971
ウェブサイトhttps://ir.newamsterdampharma.com/
企業コードNAMS
上場日Nov 23, 2022
最高経営責任者「CEO」Davidson (Michael Harvey)
NewAmsterdam Pharma Company NVの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
10.36K
+3400.00%
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
3.40K
+3400.00%
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
3.40K
+3400.00%
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
Ms. Juliette Audet
Ms. Juliette Audet
Chief Business Officer
Chief Business Officer
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Nicholas Downing, M.D.
Dr. Nicholas Downing, M.D.
Director
Director
--
--
Ms. Janneke Van Der Kamp
Ms. Janneke Van Der Kamp
Temporary Non-Executive Director
Temporary Non-Executive Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
10.36K
+3400.00%
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
3.40K
+3400.00%
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
3.40K
+3400.00%
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Wed, Nov 19
更新時刻: Wed, Nov 19
株主統計
種類
株主統計
株主統計
比率
Frazier Life Sciences Management, L.P.
14.73%
RA Capital Management, LP
8.94%
Capital World Investors
8.66%
Forbion Capital Partners
8.12%
Viking Global Investors LP
5.71%
他の
53.83%
株主統計
株主統計
比率
Frazier Life Sciences Management, L.P.
14.73%
RA Capital Management, LP
8.94%
Capital World Investors
8.66%
Forbion Capital Partners
8.12%
Viking Global Investors LP
5.71%
他の
53.83%
種類
株主統計
比率
Investment Advisor
29.12%
Investment Advisor/Hedge Fund
23.40%
Venture Capital
20.18%
Private Equity
14.73%
Hedge Fund
13.05%
Research Firm
2.37%
Family Office
1.70%
Sovereign Wealth Fund
1.00%
Individual Investor
0.56%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
314
117.45M
103.58%
-6.71M
2025Q3
283
121.74M
107.54%
+4.12M
2025Q2
263
127.89M
114.87%
+4.67M
2025Q1
255
126.71M
112.87%
+7.17M
2024Q4
216
108.34M
98.72%
+13.96M
2024Q3
194
82.73M
88.90%
-12.05M
2024Q2
184
81.92M
90.19%
-12.22M
2024Q1
155
81.92M
90.50%
-4.21M
2023Q4
117
72.34M
86.57%
-9.73M
2023Q3
116
71.44M
85.50%
-13.42M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Frazier Life Sciences Management, L.P.
16.70M
14.73%
--
--
Nov 01, 2025
RA Capital Management, LP
10.14M
8.94%
--
--
Sep 30, 2025
Capital World Investors
9.82M
8.66%
+1.43M
+17.11%
Sep 30, 2025
Forbion Capital Partners
9.21M
8.12%
-1.37M
-12.92%
Sep 30, 2025
Viking Global Investors LP
6.48M
5.71%
-503.00K
-7.21%
Sep 30, 2025
Bain Capital Life Sciences Investors, LLC
5.67M
5%
-4.80M
-45.83%
Dec 02, 2025
Fidelity Management & Research Company LLC
5.39M
4.76%
+3.57M
+195.28%
Sep 30, 2025
Deerfield Management Company, L.P.
4.27M
3.76%
-849.26K
-16.60%
Sep 30, 2025
Wellington Management Company, LLP
4.02M
3.55%
+697.13K
+20.98%
Sep 30, 2025
Jennison Associates LLC
4.20M
3.7%
+1.25M
+42.51%
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Global X Guru Index ETF
1.82%
ALPS Medical Breakthroughs ETF
1.81%
Virtus LifeSci Biotech Clinical Trials ETF
1.22%
First Trust Small Cap Growth AlphaDEX Fund
1.05%
First Trust NASDAQ Pharmaceuticals ETF
0.83%
Capital Group US Small and Mid Cap ETF
0.68%
ProShares Ultra Nasdaq Biotechnology
0.57%
Invesco Dorsey Wright SmallCap Momentum ETF
0.55%
First Trust Small Cap Core Alphadex Fund
0.43%
Invesco Nasdaq Biotechnology ETF
0.42%
詳細を見る
Global X Guru Index ETF
比率1.82%
ALPS Medical Breakthroughs ETF
比率1.81%
Virtus LifeSci Biotech Clinical Trials ETF
比率1.22%
First Trust Small Cap Growth AlphaDEX Fund
比率1.05%
First Trust NASDAQ Pharmaceuticals ETF
比率0.83%
Capital Group US Small and Mid Cap ETF
比率0.68%
ProShares Ultra Nasdaq Biotechnology
比率0.57%
Invesco Dorsey Wright SmallCap Momentum ETF
比率0.55%
First Trust Small Cap Core Alphadex Fund
比率0.43%
Invesco Nasdaq Biotechnology ETF
比率0.42%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
